Meta Information
ID:cjc-1295
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/dietary/high-carbohydrate-meal
Target name:
High Carbohydrate or High Fat Meal
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
2
Description:
Elevated blood sugar and insulin from carbohydrate or fat-rich meals strongly inhibit the pituitary gland's release of growth hormone, blunting the effect of CJC-1295.
Actionable advice:
Administer at least 2 hours after your last meal and wait at least 1 hour before eating.
Target id:
/class/ghrps-ghrhs
Target name:
Growth Hormone Releasing Peptides (e.g., Ipamorelin)
Severity:
major
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
CJC-1295 (a GHRH) and GHRPs act on different receptors in the pituitary, leading to a powerful synergistic release of growth hormone far greater than either compound alone.
Actionable advice:
For maximum effect, administer simultaneously with a GHRP like Ipamorelin.
Target id:
/condition/active-cancer
Target name:
Active Cancer / Malignancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Growth hormone (GH) and its primary mediator, IGF-1, are potent cellular growth promoters (mitogens) and can accelerate the growth of existing tumors.
Actionable advice:
Absolutely contraindicated; do not use if you have any form of active cancer.
Target id:
/biomarker/igf-1
Target name:
IGF-1 Monitoring
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
CJC-1295 is designed to increase IGF-1 levels; monitoring is essential to ensure levels remain within a safe and effective range and to avoid side effects of overdose.
Actionable advice:
Regularly test IGF-1 levels to guide dosing and ensure they remain in a safe, optimal range.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The effects of synthetic GHRH analogues on fetal development are unknown and potentially harmful.
Actionable advice:
Avoid completely during pregnancy.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if CJC-1295 is excreted in human milk or what its effects would be on a nursing infant.
Actionable advice:
Avoid completely while breastfeeding.
Target id:
/condition/pituitary-disorder
Target name:
Pituitary Gland Disorders
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Stimulating a dysfunctional or tumor-affected pituitary gland can have unpredictable and potentially harmful effects on hormone regulation.
Actionable advice:
Use is contraindicated unless under the direct supervision of an endocrinologist.
Target id:
/class/somatostatin-analogs
Target name:
Somatostatin Analogs
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Somatostatin is the body's natural 'off switch' for growth hormone release; somatostatin analog drugs will directly block the action of CJC-1295.
Actionable advice:
Avoid concurrent use as these drugs will render CJC-1295 ineffective.
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
0
Description:
The largest natural pulse of growth hormone occurs during the first few hours of deep sleep; administering CJC-1295 before bed amplifies this natural rhythm.
Actionable advice:
Administer within 30 minutes of going to bed on an empty stomach.
Target id:
/condition/diabetes-mellitus
Target name:
Diabetes Mellitus
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Growth hormone has a counter-regulatory effect to insulin, meaning it can raise blood glucose levels and increase insulin resistance, potentially disrupting glycemic control.
Actionable advice:
Use with extreme caution under medical supervision, with frequent blood glucose monitoring.
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
By raising blood glucose, CJC-1295 may counteract the effects of diabetes medications, potentially requiring dose adjustments to maintain glycemic control.
Actionable advice:
Consult your physician before use, as dosages of your diabetes medications may need to be adjusted.
Target id:
/class/hyperglycemic-agents
Target name:
Drugs that Raise Blood Sugar (e.g., Corticosteroids)
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Medications that raise blood sugar, such as corticosteroids, increase insulin and somatostatin, both of which inhibit growth hormone release and will reduce the effectiveness of CJC-1295.
Actionable advice:
Avoid concurrent use if possible, as the effectiveness of CJC-1295 will be significantly reduced.
Target id:
/intervention/intermittent-fasting
Target name:
Intermittent Fasting
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Fasting naturally lowers insulin and increases ghrelin, creating an ideal physiological environment for maximal growth hormone release when stimulated by CJC-1295.
Actionable advice:
Administer your dose during your fasting window for optimal results.
Target id:
/condition/carpal-tunnel-syndrome
Target name:
Carpal Tunnel Syndrome
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
A common side effect of elevated growth hormone is fluid retention, which can cause or exacerbate swelling and compression of the median nerve within the carpal tunnel.
Actionable advice:
Discontinue use if symptoms of carpal tunnel (hand numbness, pain) appear or worsen.
Target id:
/biomarker/fasting-glucose
Target name:
Fasting Glucose
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Because growth hormone can impair insulin sensitivity, it is important to monitor fasting glucose and HbA1c to detect any negative changes in glucose metabolism.
Actionable advice:
Periodically check fasting glucose and HbA1c while using this peptide.
Target id:
/intervention/resistance-training
Target name:
Resistance Training
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
0
Description:
Both resistance training and CJC-1295 stimulate growth hormone release; combining them may offer a modest synergistic benefit for recovery and muscle protein synthesis.
Actionable advice:
Consider administering your dose 30 minutes prior to a workout on an empty stomach.
Target id:
/biomarker/prolactin
Target name:
Prolactin
Severity:
minor
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
While less common with GHRH analogs than with some GHRPs, secretagogues can sometimes increase prolactin levels, which may warrant monitoring.
Actionable advice:
Consider checking prolactin levels, especially if symptoms like gynecomastia or lactation occur.